NASDAQ:EKSO - Ekso Bionics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.73 -0.01 (-0.57 %)
(As of 06/20/2018 09:10 AM ET)
Previous Close$1.74
Today's Range$1.72 - $1.78
52-Week Range$1.02 - $4.77
Volume126,300 shs
Average Volume356,597 shs
Market Capitalization$105.02 million
P/E Ratio-1.94
Dividend YieldN/A
Beta-0.68
Ekso Bionics logoEkso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company's Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.

Receive EKSO News and Ratings via Email

Sign-up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry General industrial machinery,
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EKSO
CUSIPN/A
Phone510-984-1761

Debt

Debt-to-Equity Ratio0.29
Current Ratio2.79
Quick Ratio2.50

Price-To-Earnings

Trailing P/E Ratio-1.94
Forward P/E Ratio-3.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.35 million
Price / Sales14.20
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book4.81

Profitability

EPS (Most Recent Fiscal Year)($0.89)
Net Income$-29,120,000.00
Net Margins-340.49%
Return on Equity-184.66%
Return on Assets-94.96%

Miscellaneous

Employees92
Outstanding Shares60,350,000

Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions

What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?

Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings Inc (NASDAQ:EKSO) released its earnings results on Monday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03. The firm earned $2.52 million during the quarter, compared to analysts' expectations of $2.98 million. Ekso Bionics had a negative return on equity of 184.66% and a negative net margin of 340.49%. View Ekso Bionics' Earnings History.

Who are some of Ekso Bionics' key competitors?

Who are Ekso Bionics' key executives?

Ekso Bionics' management team includes the folowing people:
  • Mr. Jack Peurach, Pres, CEO & Director (Age 52)
  • Mr. Maximilian Scheder-Bieschin, Chief Financial Officer (Age 56)
  • Mr. Russell L. DeLonzor, Chief Operating Officer (Age 56)
  • Mr. Gregory Davault, Chief Marketing Officer (Age 50)
  • Mr. Ruediger Hausherr, Pres of Europe

Has Ekso Bionics been receiving favorable news coverage?

News articles about EKSO stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ekso Bionics earned a news sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the company an impact score of 46.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Ekso Bionics?

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $1.73.

How big of a company is Ekso Bionics?

Ekso Bionics has a market capitalization of $105.02 million and generates $7.35 million in revenue each year. The company earns $-29,120,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Ekso Bionics employs 92 workers across the globe.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]


MarketBeat Community Rating for Ekso Bionics (EKSO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote "Outperform" if you believe EKSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.